BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Relentlessly innovative, NuVasive develops and markets minimally disruptive surgical products and procedures for the spine. From its inception, it has focused on creating products, such as its nerve avoidance monitoring system, that contribute to faster, less invasive surgical procedures, speedier recovery times for patients, and shorter hospital stays.
NuVasive went public in 2004.
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.